Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Three-Year Outcomes after CTA with 2-Stent Technique Vs. Provisional Stenting for Complex Bifurcation Lesions

The prevalence of coronary lesions with bifurcation involvement is about 20% in patients undergoing coronary angiography (CTA). While provisional stenting is overall the most accepted technique, the 2018 myocardial revascularization guidelines recommend the 2-stent technique for complex bifurcation lesions, defined as side branch with lesion >5mm, distal reference diameter of the side branch ≥2.75, or difficulty in accessing the side branch prior stent implantation in the main vessel. 

Resultado a 3 años luego de ATC con técnica de 2- stents vs Provisional stent por bifurcaciones complejas

Prospective, multicenter, randomized study DEFINITION II reported a significant improvement in clinical outcomes after one year using the 2-stent technique in patients with complex coronary bifurcation lesions. However, there is no long-term information on the benefit of these techniques.

The purpose of this study was to evaluate the 3-year follow-up clinical outcomes after the 2-stent technique vs. provisional stenting.

The primary endpoint (PEP) was treated lesion failure (TLF), which included cardiovascular death, treated-vessel-related acute myocardial infarction (AMI), and clinically driven repeat vascularization of the treated vessel (TVF). The safety endpoint was stent thrombosis.

The study enrolled 635 patients, 328 in the 2-stent arm and 325 in the provisional stenting (PS) arm. Mean patient age was 63 years old, and most subjects were male. Of all patients, 34% had diabetes, and the most frequent clinical presentation was unstable angina. 

In the PS arm, 22% of patients needed a side branch stent due to suboptimal outcomes. Furthermore, side branch pre-treatment increased the need for additional stent use in the PS arm (32% vs. 14%, p < 0,001). There were no differences between arms in POT and kissing balloon use. The intravascular ultrasound (IVUS) use rate was 27%.

Read also: Same Day Discharge in NSTE-ACS: Is It Possible?

The 3-year PEP was 16% in the PS arm and 10% in the 2-stent arm (hazard ratio [HR]: 0.63; 95% confidence interval [CI]: 0.41-0.97; p = 0.035). There was a predominance of increased AMI (8.0% vs. 3.7%; HR: 0.63; 95% CI: 0.41-0.97; p =0.035) and treated vessel revascularization (HR: 0.50; 95% CI: 0.26-0.96; p = 0.038) in the PS arm. There was no difference in the safety endpoint between the two arms.

Among patients in the PS arm, patients requiring 2 stents had higher TLF rates, which was attributed to the high rate of repeat revascularization. Finally, patients who experienced intraprocedural complications had a higher rate of TLF at 1 year compared with patients with no complications.

Conclusion

The risk of future events remains present for patients with complex coronary bifurcation lesions with no events 1 year after the procedure.

Dr. Andrés Rodríguez

Dr. Andrés Rodríguez.
Member of the Editorial Board of SOLACI.org.

Original Title: 3-Year Outcomes After 2-Stent With Provisional Stenting for Complex Bifurcation Lesions Defined by DEFINITION Criteria.

Reference: Jing Kan, MBBS et alJ Am Coll Cardiol Intv 2022;15:1310–1320.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

GLUCO-TAVI | Can Glucocorticoids Reduce the Need for Permanent Pacemaker Implantation After TAVI?

Despite the expansion of transcatheter aortic valve implantation (TAVI) indications, cardiac conduction disturbances (CCD) and the need for permanent pacemaker implantation (PPI) remain the...

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...